Hematologic Malignancy
Peripheral T-Cell Lymphoma, Not Otherwise Specified
CI-CAN-00008233Explore in graph →
Hematologic72 active trials2 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00008233Explore in graph →
Clinical trials
299 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (41)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04040491 | PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma | unknown | Phase 4 | 100 | Mingzhi ZhangOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT03631862 | Treatment of Newly Diagnosed Peripheral T-cell Lymphoma | unknown | Phase 4 | 100 | Zhengzhou UniversityOTHER | 1 | Aug 15, 2018 | clinicaltrials |
| NCT03071822 |
| Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas |
| unknown |
| Phase 4 |
| 50 |
| The University of Hong KongOTHER |
| 1 |
| Jun 11, 2018 |
| clinicaltrials |
| NCT03150602 | A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy | unknown | Phase 4 | 22 | Taiwan Mundipharma Pharmaceuticals Ltd.INDUSTRY | 1 | May 12, 2017 | clinicaltrials |
| NCT01664975 | Treatment of Peripheral T-cell Lymphoma | completed | Phase 4 | 100 | Mingzhi ZhangOTHER | 1 | Oct 5, 2016 | clinicaltrials |
Data updated 23 days agoSource updated May 12, 2020source: clinicaltrials